Table 1.
Study characteristics of trials on neoadjuvant immunotherapy for patients with resectable non-small cell lung cancer.
| Study | Institution | Recruitment Period |
F/U (Months) | Immunotherapy | Chemotherapy | Adjuvant Immunotherapy |
|---|---|---|---|---|---|---|
| Rothschild, 2021 [5] | 14 institutions in Sweden | 6/2016–1/2019 | 29 | Durvalumab (750 mg) 2 cycles | Cisplatin + docetaxel | Durvalumab 26 cycles |
| NADIM Provencio, 2021 [6] Roman, 2021 [7] |
18 institutions in Spain | 4/2017–8/2018 | 24 | Nivolumab (360 mg) 3 cycles | Paclitaxel + carboplatin 3 cycles | Nivolumab (240 mg q2w for 4 months then 480 mg q4w for 8 months) |
| NEOSTAR Cascone, 2021 [8] |
MD Anderson Cancer Center, USA |
6/2017–11/2018 | 22 | Nivolumab (3 mg/kg on D1, 15, 29) 3 cycles or Nivolumab 3 cycles + Ipilimumab (1 mg/kg on D1 only) |
NS | NS |
| NEOMUN Eichhorn, 2021 [9] |
Heidelberg University Hospital, Germany |
5/2018–3/2020 | NS | Pembrolizumab (200 mg) 2 cycles |
NS | NS |
| Tong, 2021 [10] | Mayo Clinic; Dartmouth- Hitchcock; Duke University, USA |
4/2017–2/2019 | 11 | Pembrolizumab (200 mg) 2 cycles |
NS | Pembrolizumab 4 cycles |
| Shu, 2020 [11] | Columbia University; MGH; BWH; Vanderbilt University Medical Center, USA | 5/2016–3/019 | 13 | Atezolizumab (1200 mg) 4 cycles |
Paclitaxel + carboplatin 4 cycles | NS |
| Bott, 2019 [12] Forde, 2018 [13] |
Johns Hopkins; MSKCC, USA | 8/2015–10/2016 | 20 | Nivolumab (3 mg/kg) 2 cycles | NS | NS |
| Gao, 2020 [14] | PUMC | 3/2018–3/2019 | 3 | Sintilimab (200 mg) 2 cycles | NS | Sintilimab |
| Yang, 2018 [15] | Duke University Medical Centre, USA | 3/2013–12/2015 | 24 | Ipilimumab (10 mg/kg) 2 cycles |
Paclitaxel + cisplatin or carboplatin 3 cycles | NS |
| Wang, 2021 [16] | Zhejiang Cancer Hospital, China | 9/2019–7/2020 | NS | Nivolumab (200 mg), pembrolizumab (100 mg), camrelizumab (200 mg) 2 cycles |
Paclitaxel + carboplatin q3w | NS |
| Shen, 2021 [17] | Zhejiang Cancer Hospital, China | 6/2019–7/2020 | 7 | Pembrolizumab (2 mg/kg) 2 cycles | Paclitaxel + carboplatin 2 cycles | NS |
| Jiang, 2021 [18] | Shanghai Chest Hospital, China | 9/2018–4/2020 | NS | Pembrolizumab or nivolumab 3 cycles | NS | Variable |
| Huang, 2021 [19] | Qingdao University Hospital, China | 6/2019–12/2020 | NS | Nivolumab (3 mg/kg) 2 cycles | NS | NS |
| Duan, 2021 [20] | Tangdu Hospital; Chongqing Medical University, China | 6/2018–6/2020 | NS | Sintilimab or nivolumab or pembrolizumab, 3–4 cycles | Pemetrexed + cisplatin or Paclitaxel + nedaplatin or Gemcitabine + nedaplatin or Paclitaxel + Carboplatin 3–4 cycles |
NS |
| Chen, 2021 [21] | Shanghai Chest Hospital, China | 1/2019–3/2020 | 18 | Pembrolizumab 4 cycles or nivolumab 2 cycles | Carboplatin and paclitaxel | Variable |
| Chen, 2021 [22] | Tianjin Medical University Cancer Institute and Hospital |
1/2019–5/2020 | 13 | Pembrolizumab (2 mg/kg) 2 cycles q3w |
Cisplatin + paclitaxel liposome or pemetrexed q3w | NS |
MSKCC, Memorial Sloan Kettering Cancer Centre; PUMC, Peking Union Medical College; MGH, Massachusetts General Hospital; BWH, Brigham and Women’s Hospital; F/U, Follow-up; NS, Not specified.